Testing the Addition of the Immunotherapy Drug Pembrolizumab to the Usual Chemotherapy Treatment (Paclitaxel and Carboplatin) in Stage III-IV or Recurrent Endometrial Cancer

This study is looking for women who have been diagnosed with certain types of womb cancer that is either advanced (Stage III or IV) or has returned after previous treatment. Your doctors will need to check your previous test results, especially specific details about your cancer from biopsy reports.

You might be able to join if you haven't had chemotherapy for your womb cancer before, or if you had it a long time ago (at least 12 months before joining the study). You may also have had radiotherapy or hormone therapy in the past, but these treatments must have finished at least 4 weeks before you join the study. Generally, participants must be at least 18 years old.

There are also other medical checks your doctor will need to do to make sure the study treatment is safe for you. These will include checking how well your organs are working, like your heart, liver, and kidneys.

If you decide to take part in this study, you would first have health checks, including a review of your medical history, blood tests, and scans (like CT scans) to assess your cancer. You would then be randomly assigned to receive either the standard chemotherapy (paclitaxel and carboplatin) or the standard chemotherapy plus pembrolizumab. This means a computer decides which treatment group you are in, like flipping a coin, so it's fair.

Both treatments involve receiving infusions, usually in cycles over several months. You would have regular visits to the hospital for these treatments, blood tests, and medical check-ups to monitor your health and how the treatment is working. You will also fill out questionnaires about your quality of life and how you are feeling. After the treatment phase, you would have follow-up appointments and scans to track your progress over time. The total duration of active treatment and follow-up can vary.